Keros Therapeutics, Inc. — Earnings Quality Grade B
KROS · Healthcare
Generally healthy
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 5 days, change -277 days YoY
AR growth 30.1% vs revenue growth 6775.0%
Revenue grew 6775.0% but CFFO only 166.8%
Expense Quality
No material inventory
CapEx growth -19.7% vs revenue 6775.0%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO/NI = 1.24. Profits backed by cash
FCF $0.1B, FCF/NI = 1.22
Accruals ratio = -6.1%. Low accruals
Cash $0.3B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = 0.2x. Healthy
Other assets -58.7% vs revenue 6775.0%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 2/3 years
No goodwill
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor KROS continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25